We are committed to helping patients suffering from illness or injury lead active lives, We are researching and developing innovative treatments for brain diseases, which is our specialty, so that patients suffering from illness or injury can lead active lives.

Redox NanoParticle CTB211 Drug Discovery Business

CTB211 is a polymeric micelle formulation with a particle diameter of 20-30 nm, in which the nitroxyl radical TEMPO, a radical scavenger and scavenging agent, is covalently supported on a block copolymer. It has been researched and developed as a redox nanoparticle at the University of Tsukuba.
The biological half-life of TEMPO has been extended from 15 seconds to 60 minutes by improving its blood retention, and its pH responsiveness has shown neuroprotective effects by eliminating reactive oxygen species generated in various cells of the central nervous system, and it is expected to be applied to various diseases and injuries.


CTB211 for Ischemic Stroke

Stroke is the third leading cause of death in Japan and the second leading cause of death in the world, with an estimated 300,000 people per year in Japan and 800,000 people per year in the United States.
Recanalization therapy (thrombus retrieval therapy) for acute main cerebral artery occlusion has been rapidly gaining popularity since 2015 as a highly effective treatment. However, although it is a highly effective therapy that improves the outcome of ischemic stroke patients, more than 50% of patients still do not respond adequately and have a poor outcome, requiring support or nursing care or becoming bedridden or dying. The main cause of inadequate response to thrombus retrieval therapy is thought to be cerebral ischemia-reperfusion injury caused by reactive oxygen species and free radicals that occur after recanalization, leading to cerebral infarction, worsening of cerebral edema, and intracranial hemorrhage, but at present there is no nationally approved treatment that has been proven effective.
CTB211 protects neurons by scavenging reactive oxygen species and is expected to be highly effective, and has been shown to be effective in non-clinical studies.